NEW YORK (GenomeWeb) – Women with early-stage breast cancer who are at high clinical risk of recurrence might not need adjuvant chemotherapy if they are at low genomic risk.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.